1. Home
  2. EPOW vs ATOS Comparison

EPOW vs ATOS Comparison

Compare EPOW & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

N/A

Current Price

$3.66

Market Cap

24.2M

ML Signal

N/A

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

N/A

Current Price

$2.17

Market Cap

25.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPOW
ATOS
Founded
2014
2009
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
25.9M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
EPOW
ATOS
Price
$3.66
$2.17
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
24.2K
★ 88.7K
Earning Date
05-15-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.53
52 Week High
$7.66
$7.56

Technical Indicators

Market Signals
Indicator
EPOW
ATOS
Relative Strength Index (RSI) 49.98 43.14
Support Level $0.55 $2.09
Resistance Level $5.29 $2.60
Average True Range (ATR) 0.47 0.20
MACD -0.08 -0.05
Stochastic Oscillator 31.30 20.32

Price Performance

Historical Comparison
EPOW
ATOS

About EPOW Sunrise New Energy Co. Ltd

E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Share on Social Networks: